Delivering a boost to immuno-oncology and immunotherapy
researchers, Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced
that it has entered into a strategic partnership with leading life
science research and clinical diagnostics products company Bio-Rad
Laboratories, Inc. (NYSE: BIO and BIOb). Under the terms of the
agreement, Bio-Rad’s exceptionally bright, high-performing new
StarBright™ Dyes will be available to Cytek to develop and
commercialize reagent products to support high-parameter
applications on Aurora and Northern Lights™ flow cytometry systems.
Bio-Rad’s StarBright Dyes have been designed to
be stable with superior brightness, narrow excitation and emission
characteristics for minimized spillover and improved resolution of
specific cell populations, allowing researchers to build bigger,
better panels.
Bio-Rad’s StarBright Dyes complement Cytek’s
cFluor® family of proprietary dyes, providing a wider variety of
color options for highly multiplexed panel design and application
development. Cytek plans to develop and optimize single vial
reagents and multicolor panels using StarBright Dyes for the more
than 1,500 Cytek Full Spectrum Profiling™ (FSP™) instruments
already deployed across more than 40 countries.
“Our focus has always been to provide a complete
cell analysis solution to our customers, and the addition of
Bio-Rad StarBright Dyes to our FSP platform is a big win for
researchers conducting multiparameter experiments,” noted Wenbin
Jiang, CEO of Cytek Biosciences. “Researchers will be able to
expand multiparameter analysis into violet and UV channels with
Cytek-optimized reagents, unleashing the full power of FSP
technology to obtain better resolution and a deeper understanding
of populations.”
Bio-Rad StarBright Dye conjugates can also be
integrated seamlessly into Cytek immunoprofiling assays. These
easy-to-use, pre-optimized panels are designed by Cytek’s
scientists, freeing researchers from time-consuming,
labor-intensive and costly panel design and optimization.
“Cytek has made a name for itself as a pioneer
that has shifted the conventional dynamics surrounding flow
cytometry, making our unique new reagents a perfect fit for their
instruments,” said Hilary Latham, marketing director for Bio-Rad.
“We are proud to team with Cytek to bring more high-quality reagent
choices on both violet and UV channels to researchers.”
For more information about Cytek’s
cFluor reagents and kits, please visit
https://cytekbio.com/collections/reagents.
About Cytek Biosciences,
Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading
cell analysis solutions company advancing the next generation of
cell analysis tools by delivering high-resolution, high-content and
high-sensitivity cell analysis utilizing its patented Full Spectrum
Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the
power of information within the entire spectrum of a fluorescent
signal to achieve a higher level of multiplexing with precision and
sensitivity. Cytek’s FSP platform includes its core instruments,
the Aurora and Northern Lights™ systems; its cell sorter, the
Aurora CS; and reagents, software and services to provide a
comprehensive and integrated suite of solutions for its customers.
Cytek is headquartered in Fremont, California with offices and
distribution channels across the globe. More information about the
company and its products is available at www.cytekbio.com.
Other than Cytek’s Northern Lights CLC system
and certain reagents for use therewith, which are available for
clinical use in countries where the regulatory approval has been
obtained from the local regulatory authorities, including China and
the European Union, Cytek’s products are for research use only and
not for use in diagnostic procedures. Please contact your local
sales representatives for the status of local regulatory
approval.
Cytek, cFluor, Full Spectrum Profiling, FSP and
Northern Lights are trademarks or registered trademarks of Cytek
Biosciences, Inc.
In addition to filings with the Securities and
Exchange Commission (SEC), press releases, public conference calls
and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn
page and corporate Twitter account as channels of distribution
of information about its company, products, planned financial and
other announcements, attendance at upcoming investor and industry
conferences and other matters. Such information may be deemed
material information and Cytek may use these channels to comply
with its disclosure obligations under Regulation FD. Therefore,
investors should monitor Cytek’s website, LinkedIn page, and
Twitter account in addition to following its SEC filings, news
releases, public conference calls and webcasts.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 as
contained in Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
which are subject to the “safe harbor” created by those sections.
All statements, other than statements of historical facts, may be
forward-looking statements. Forward-looking statements generally
can be identified by the use of forward-looking terminology such as
“may,” “might," "will,” “should,” “expect,” “plan,” “anticipate,”
“could,” “intend,” “target,” “project,” “contemplate,” “believe,”
“estimate,” “predict,” “potential” or “continue” or the negatives
of these terms or variations of them or similar terminology, but
the absence of these words does not mean that a statement is not
forward-looking. These forward-looking statements include
statements regarding Cytek Biosciences’ business strategies and
product plans, including plans to develop, optimize and
commercialize single vial reagents and multicolor panels using
StarBright Dyes to support high-parameter applications on Aurora
and Northern Lights™ flow cytometry systems. These statements are
based on management’s current expectations, forecasts, beliefs,
assumptions and information currently available to management.
These statements also deal with future events and involve known and
unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially
different from the information expressed or implied by these
forward-looking statements. Factors that could cause actual results
to differ materially include risks and uncertainties such as those
relating to market conditions; the ongoing COVID-19 pandemic; Cytek
Biosciences’ dependence on certain sole and single source
suppliers; competition; market acceptance of Cytek Biosciences’
current and potential products; Cytek Biosciences’ ability to
manage the growth and complexity of its organization; Cytek
Biosciences’ ability to maintain, protect and enhance its
intellectual property; and Cytek Biosciences’ ability to continue
to stay in compliance with its material contractual obligations,
applicable laws and regulations. You should refer to the section
entitled “Risk Factors” set forth in Cytek Biosciences’ Quarterly
Report on Form 10-Q filed with the SEC on November 9,
2022 and other filings Cytek Biosciences makes with the SEC from
time to time for a discussion of important factors that may cause
actual results to differ materially from those expressed or implied
by Cytek Biosciences’ forward-looking statements. Although Cytek
Biosciences believes that the expectations reflected in the
forward-looking statements are reasonable, it cannot provide any
assurance that these expectations will prove to be correct nor can
it guarantee that the future results, levels of activity,
performance and events and circumstances reflected in the
forward-looking statements will be achieved or occur. The
forward-looking statements in this press release are based on
information available to Cytek Biosciences as of the date hereof,
and Cytek Biosciences disclaims any obligation to update any
forward-looking statements provided to reflect any change in its
expectations or any change in events, conditions, or circumstances
on which any such statement is based, except as required by law.
These forward-looking statements should not be relied upon as
representing Cytek Biosciences’ views as of any date subsequent to
the date of this press release.
Media Contact:Stephanie
OlsenLages & Associates(949) 453-8080stephanie@lages.com
Investor Contact:Paul
GoodsonHead of Investor RelationsCytek
Biosciencespgoodson@cytekbio.com
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Sep 2023 to Sep 2024